Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs > Bioelectronics Corp. (BIEL)

Hey, it's great news. Their other products

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
kidnova Member Profile
Followed By 5
Posts 2,424
Boards Moderated 0
Alias Born 10/15/10
160x600 placeholder
Facebook Survey Shows UK Consumers Experience 52% Reduction in Intractable Chronic Pain with ActiPatch® Therapy in Musculosk... "PR Newswire (US)" - 8/26/2014 8:30:00 AM
BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live "PR Newswire (US)" - 8/18/2014 7:20:00 PM
BioElectronics President Letter to Shareholders "PR Newswire (US)" - 8/4/2014 8:30:00 AM
BioElectronics "Try It and Tell Us" Facebook Social Media Program Builds Momentum and User Testimonials "PR Newswire (US)" - 6/30/2014 8:30:00 AM
BioElectronics' OTC ActiPatch® Musculoskeletal Pain Therapy Clinically Proven to Reduce Osteoarthritis Pain and Disability "PR Newswire (US)" - 5/14/2014 8:30:00 AM
Osteoarthritis Study shows ActiPatch® Therapy Significantly Relieves Knee Pain "PR Newswire (US)" - 4/16/2014 9:00:00 AM
Clear Channel Bus. Talk Radio's 'The Traders Network' Interview With Andrew J. Whelan, CEO of BioElectronics Corp Now Availab... "Marketwired" - 4/15/2014 9:55:11 AM
BioElectronics Device Alleviates Dental Surgical Trauma "PR Newswire (US)" - 3/25/2014 8:30:00 AM
BioElectronics CEO Andrew Whelan to Be Interviewed Live Wednesday on Clear Channel Business Talk Radio "Marketwired" - 3/24/2014 8:19:47 AM
Depository Trust Company (DTC) Lifts Chill on BioElectronics Shares "PR Newswire (US)" - 3/20/2014 8:30:00 AM
BioElectronics' ActiPatch® and Allay® are Now Available in Austria "PR Newswire (US)" - 3/18/2014 8:30:00 AM
BioElectronics Appoints Deepak Kotak, MD, Esq as Executive Vice President "PR Newswire (US)" - 3/11/2014 8:30:00 AM
BioElectronics Wins High Commendation In "Most Innovative New OTC Product Award" From OTC Bulletin "PR Newswire (US)" - 3/7/2014 9:49:00 AM
New Education Campaign Seeks to Teach Consumers, Medical Pros to Fight Pain Without Drugs "PR Newswire (US)" - 3/4/2014 8:30:00 AM
BioElectronics Researchers And Clinicians Support FDA's Position To Reclassify Shortwave Medical Devices To Class II "PR Newswire (US)" - 2/27/2014 9:32:00 AM
Google Plus to feature Dr. Christine Dumas on Wednesday, February 26th "PR Newswire (US)" - 2/26/2014 10:36:00 AM
BioElectronics Announces New Product "PR Newswire (US)" - 2/25/2014 8:30:00 AM
BioElectronics Applauds FDA Recommendation to Reclassify Shortwave Medical Devices to Class II "PR Newswire (US)" - 2/21/2014 8:30:00 AM
BioElectronics' Innovative Pain Relief Products Nominated for Most Innovative New OTC Product Award and Others by OTC Bulletin "PR Newswire (US)" - 2/18/2014 8:30:00 AM
Pain Management Medical Journal Features BioElectronics' Innovative Pain Products Because Pain is Not a Druggable Disease "PR Newswire (US)" - 1/9/2014 8:30:00 AM
BioElectronics Enters the $20 Billion Dental Market "PR Newswire (US)" - 12/30/2013 9:15:00 AM
BioElectronics' ActiPatch® Musculoskeletal Pain Therapy Now Available in Boots Stores "PR Newswire (US)" - 12/9/2013 8:30:00 AM
BioElectronics' RecoveryRx® and Smart Insole™ are Now Available in Austria "PR Newswire (US)" - 11/19/2013 8:30:00 AM
kidnova   Wednesday, 05/16/12 02:18:55 PM
Re: Threepointer post# 21861
Post # of 43291 
Hey, it's great news. Their other products are already approved as class II devices in Canada however, so it's hardly unexpected that RX Recovery would get the same designation. I'm in the camp with others here that for BIEL it's FDA or bust. It's also typical of BIEL to release this type of PR on the same day that they release their less than stellar financial statements. Once the buzz dies down from this PR people will focus on the numbers, so IMO this is a good opportunity to do some trading. GL.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist